Events & Presentations
Upcoming Events
Precigen conference call to discuss fourth quarter and full year 2020 results.
The conference call may be accessed by dialing 1-888-317-6003 (Domestic US), 1-866-284-3684 (Canada) or 1-412-317-6061 (International) and providing the number 9387943 to join the Precigen Conference Call. Participants are asked to dial in 10-15 minutes in advance of the scheduled call time to facilitate timely connection to the call.
Helen Sabzevari, PhD, President and CEO, will present at the H.C. Wainwright Virtual Global Life Sciences Conference and the on-demand webcast will be available starting Tuesday, March 9, 2021 at 7:00 AM ET.
Past Events
Helen Sabzevari, PhD, President and CEO of Precigen, will present a corporate and clinical overview.
Helen Sabzevari, PhD, President and CEO of Precigen, will participate in a panel discussion hosted by Scott Gottlieb, MD, on Precision Medicine - The importance of biomarkers and cytogenetic profiling in drug discovery, development and commercialization.
Precigen hosted a virtual event to provide an update on the latest progress for its clinical pipeline. The event showcased data from several of the Company’s most advanced clinical programs, such as PRGN-3005 UltraCAR-T®, PRGN-3006 UltraCAR-T® and AG019 ActoBioticsTM.
Upcoming presentation entitled "A Phase 1/1b Safety Study of PRGN-3006 UltraCAR-T in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndrome." (Abstract 2864)
The conference call may be accessed by dialing 1-888-317-6003 (Domestic US), 1-866-284-3684 (Canada) or 1-412-317-6061 (International) and providing the number 6003292 to join the Precigen Conference Call. Participants are asked to dial in 10-15 minutes in advance of the scheduled call time to facilitate timely connection to the call. Participants may also access the live webcast through Precigen’s website at the link below.
Tim Chan, PhD, Senior Director, Immuno-Oncology of Precigen will present the poster “PRGN-3005 UltraCAR-T™: Multigenic CAR-T Cells Generated Using Non-viral Gene Delivery and Rapid Manufacturing Process for the Treatment of Ovarian Cancer”. (Abstract 6593)
Precigen held a virtual meeting for the 2020 Annual Meeting of Shareholders.
The conference call may be accessed by dialing 1-833-646-0488 (US/Canada toll-free) or 1-918-922-6615 to join the Precigen Conference Call. Participants are asked to dial in 10-15 minutes in advance of the scheduled call time to facilitate timely connection to the call. Participants may also access the live webcast through Precigen’s website at the link below.
The conference call may be accessed by dialing 1-888-317-6003 (Domestic US), 1-866-284-3684 (Canada), and 1 412-317-6061 (International) and providing the number 4230814 to join the Precigen Conference Call.
Helen Sabzevari, PhD, President and CEO of Precigen, will present Precigen’s progress to date and a 2020 look ahead
Tim Chan, PhD, Senior Director, Immuno-Oncology of Precigen will present the poster “Preclinical Characterization of PRGN-3006 UltraCAR-T™ for the Treatment of AML and MDS: Non-Viral, Multigenic Autologous CAR-T Cells Administered One Day after Gene Transfer.” (Abstract #2660)
Helen Sabzevari, PhD, President of Precigen, will present the keynote “Unleashing the potential of gene therapy using the non-viral UltraCAR-T platform for hematological and solid tumors.”
Helen Sabzevari, PhD, President of Precigen, hosted a conference call to provide Precigen business and pipeline updates
Helen Sabzevari, PhD, President of Precigen, presented at JMP Securities Life Sciences Conference.
Helen Sabzevari, PhD, President of Precigen, presented at the 8th Annual SVB Leerink Global Healthcare Conference.